Teeth Whitening Products Market Research Report and Global Industry Analysis

The global Teeth Whitening Products Market is expected to reach USD 7.40 billion by 2024. The industry is driven by the mounting consumer demand for clean and white teeth coupled with awareness about oral hygiene. Moreover, 99.2% of the people believe that smile is an important social benefit and growing consumer preference for over the counter products in countries such as Germany, France, UK, India and China are anticipated to drive the growth of the market over the forecast period.

The leading teeth whitening products manufacturing companies are focusing on R&D to enhance its product portfolio and are expanding their presence in the global market by acquiring local players of that region. For instance, in April 2017, Colgate-Palmolive acquired Ciba-Geigy, an India-based teeth whitening brand, to expand its reach towards the rural parts of India. These factors are expected to provide an impetus to the growth of the market over the next coming years.

Browse Details of Report @

https://www.hexaresearch.com/research-report/teeth-whitening-products-market

Whitening toothpaste segment holds the largest share in the market in terms of revenue and is expected to maintain its position over the forecast period. Whitening toothpaste has a major role in oral hygiene maintenance. Unhealthy lifestyle accompanied by consumption of liquor, cola, tobacco and other related products which cause discoloration of the teeth are anticipated to drive the market globally.

The whitening strips segment was valued at USD 899.8 million in 2016 and are likely to witness a significant growth as a result of rising consumer demand and the requirement for quick result formulas. Furthermore, initiatives and campaigns have taken up by leading companies such as Colgate-Palmolive, P&G and GlaxoSmithKline to create awareness among consumers to use herbal products for teeth whitening are expected to augment the growth of the market.

The increase of these market is determined mainly by consumer demand which is to be favoured by the rising living standards such as modernization, personality traits and appearance. There is a huge competition in the teeth whitening products market as the market is consolidated. The leading players are acquiring the major local players and expanding its production capacity and presence globally. The leading manufacturers in these markets are Colgate-Palmolive, Proctor & Gamble, GlaxoSmithKline, Johnson & Johnson, Unilever and Henkel.

Hexa Research has segmented the global teeth whitening products market based on type and region:

Segmentation by type, 2014 - 2024 (USD Million)

• Whitening Toothpaste

• Whitening Stripes & gels

• Others

Segmentation by region, 2014 - 2024 (USD Million)

• North America

    • U.S.

• Europe

    • Germany

    • UK

• Asia Pacific

    • China

    • India

• Central & South America

• Middle East and Africa

Key players analyzed

• Colgate-Palmolive

• GlaxoSmithKline

• Johnson & Johnson

• Proctor & Gamble

• Unilever

• Church & Dwight

• Brodie & Stone

• CCA Industries

• GO SMILE

• Henkel

Browse Related Category Market Reports @

https://www.hexaresearch.com/research-category/healthcare-industry

U.S. Medical Cannabis Market is Expected to Witness Substantial Growth till 2024

The U.S. Medical Cannabis Market is expected to be valued at USD 19.48 billion by 2024, driven by its numerous medical benefits particularly by patients suffering from cancer, chronic pain and diabetes. Favorable regulatory environment across numerous states including California and Colorado is expected to fuel the growth of the market over the next few years.

Medical Marijuana Regulation and Safety Act implemented in 2015 permits the cultivation and use of cannabis dispensaries at the state and local level which has been one of key drivers to fuel the U.S market. The rising number of states receiving approval to utilize cannabis for consumption in medical cases is expected to be one of the crucial factors to upsurge the demand for medical marijuana over the forecast period.

Browse Details of Report @ https://www.hexaresearch.com/research-report/us-medical-cannabis-market

Over the past few decades, there have been several controversies surrounding legalization of cannabis for medical purposes; however, increasing signs of medical benefits received from the consumption of cannabis has resulted in the herb being legalized across various states in the nation. The industry is expected to witness significant growth during the forecast period owing to greater consumer acceptance along with an increasing number of companies entering the market.

The symptoms and conditions that can be treated by the herb include cancer, arthritis, epilepsy, nausea, pain Alzheimer’s disease, anorexia, AIDS, HIV, glaucoma, cachexia, Crohn’s disease, migraines, and multiple sclerosis. Chronic pain accounted for 46% of the U.S. cannabis medical market share in 2016. The ability of medical marijuana to curb pain is expected to gain popularity among patients diagnosed with chronic illnesses and pain.

In 2016, solid edibles segment dominated the U.S market generating revenues worth USD 2.47 billion and is expected to continue dominating the industry over the forecast period. The future product innovation and potential growth are substantial owing to continuous development from the consumption of cannabis infused products owing to their numerous applications including lotions, bath salts, shampoo, lip balm, toothpaste, coffee pods, baked brownies cookies, candy, confectioneries, beverages, vinegar and oils.

California is known to be the first state in U.S. that legalized cannabis for medical purpose. In 2016, California recorded the highest revenue generation and is expected to grow at a CAGR of 13% over the projected period. Over the next few years, more number of state governments are expected to legalize cannabis owing to its numerous benefits which will fuel its growth over the projected period.

Hexa Research has segmented the U.S. medical cannabis market based on usage, consumption and state:

Segmentation by usage, 2014 - 2024 (USD Million)

• Chronic Pain

• Arthritis

• Migraine

• Cancer

• Others

Segmentation by consumption, 2014 - 2024 (USD Million)

• Solid Edibles

• Inhalation

• Liquid Edibles

• Topical

Segmentation by state, 2014 - 2024 (USD Million)

• California

• Colorado

• Washington

• Arizona

• Michigan

Key players analyzed

• American Cannabis

• Canopy Growth Corporation

• Greengro Technologies

• Medical Marijuana Inc.

• United Cannabis

• Terra Tech Corp.

• Mentor Capital, Inc

• Cannabis Sativa, Inc.

• GBSciences, Inc.

• The Green Solution

Browse Related Category Market Reports @
https://www.hexaresearch.com/research-category/healthcare-industry

Global Biosimilars Market is Expected to Reach USD 13.1 Billion by 2024

             

The Global Biosimilars Market is expected to reach USD 13.1 billion by 2024 on account of increase in the prevalence of chronic diseases such as cancer, diabetics, cardiac disorders and autoimmune diseases. Rising demand for the cost-effective therapies is expected to drive the market in the forecast period. Biosimilars are about 30% cheaper than their counterpart biologics. Furthermore, the patent expiry of the blockbuster drugs is anticipated to provide a lucrative opportunity for the growth of biosimilars. For instance, a patent for Bevacizumab, sold under the trade name Avastin is expiring in 2019.

Moreover, increasing government initiatives, speedy drug approvals and reimbursement policies are expected to boost the market for the biosimilars in the study period. Also, market giants are adopting merger & acquisition strategies to increase their product portfolio. For instance, in 2015, Pfizer, Inc. acquired Hospira, a key player in biosimilars market.

Browse Details of Report @ https://www.hexaresearch.com/research-report/biosimilars-market

In 2016, oncology was the largest segment, accounting for 32% market share. Increasing prevalence of cancer across the globe is the key factor driving the growth of the market over the forecast period. For instance, according to the American Cancer Society, an estimated 1.6 lakh people suffered from cancer in 2016. Also, increasing government initiatives to provide cost effective treatment to cure deadly diseases will boost the penetration of biosimilar in developing countries which in turn will increase the market for biosimilar over the forecast period. For instance, WHO launched a pilot program for prequalifying biosimilar drug, making some of the most expensive treatments for cancer more widely available in developing countries. Under this initiative, WHO has focused on two essential drug rituximab (principally used for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia), and trastuzumab (for the treatment of breast cancer).

In terms of region, Europe dominates the market for biosimilars followed by North America. The dominance of Europe is due speedy approval of the drug by European regulatory bodies. Furthermore, improving healthcare infrastructure and ageing population is expected to drive the market over the forecast period. However, Asia Pacific is projected to be the fastest growing region owing to the increasing disposable income of middle-class families, growing medical tourism and improving healthcare infrastructure. Furthermore, increasing investment in R&D activities by pharmaceutical giants is expected to boost the market in the projected period.

Hexa Research has segmented the global biosimilars market based on indication and region:

Segmentation by indication, 2014 - 2024 (USD Million)
• Blood Disorders
• Oncology
• Chronic & Autoimmune Diseases
• Others

Segmentation by region, 2014 - 2024 (USD Million)
• North America
    • U.S.
• Europe
    • Germany
• Asia Pacific
    • China
    • India
    • Japan
• Rest of the world

Key players analyzed:
• Dr. Reddy’s Laboratories Ltd
• Mylan
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
• Pfizer Inc.
• Sandoz International GmbH
• Teva Pharmaceuticals Industries Ltd.
• Amgen Inc.
• STADA Arzneimittel AG
• Biocon
• F. Hoffmann-La Roche Ltd.

Browse Related Category Market Reports@ https://www.hexaresearch.com/research-category/healthcare-industry

Visceral Pain Market is Expected to Witness Substantial Growth due to Increasing Geriatric Population Globally

The Global Visceral Pain Market is expected to reach USD 14.22 billion by 2024, driven by the increasing geriatric population globally. Increasing prevalence of visceral pain and rising awareness regarding the same is projected to drive market growth over the forecast period.

In 2016, North America held the majority of share in global visceral pain market owing to the increasing healthcare expenditure. Additionally, the high prevalence of Crohn’s and irritable bowel is expected to propel the growth of the market over the projected period.

Asia Pacific is expected to be the fastest growing region with the CAGR of 6.2%. The increase in the healthcare infrastructure and presence of a large pool of patients is projected to drive the demand for the visceral pain industry during the forecast period.

Analgesic segment dominated the market for the visceral pain with the market share of 60.4%. The major share of the analgesic segment is attributed to the increasing penetration of generic drug. Furthermore, rising healthcare expenditure and an increasing use of opioids for the chronic pain are the key factors attributing to its share.

In 2016, Crohn’s disease was the largest indication segment for the visceral pain market contributing to 41.4% of the market share. Increasing occurrences of Crohn’s disease across the globe coupled with the growing drug therapies for the treatment of the disease are the key factors attributing to the major share. Furthermore, increasing awareness about Crohn’s disease is fueling the demand for treatment therapies.

Key market players include Pfizer, Johnson & Johnson, Abbvie, Takeda, Allergan, and AstraZeneca. These companies are focusing on R&D for visceral pain therapeutics. These companies are likely to cater their products to patients affected by visceral pain. The growth of the geriatric population is expected to help in augmenting the profits of these companies over the next few years.

Growing focus on research and development by pharmaceutical companies and government initiatives are expected to boost the visceral pain industry during the forecast period. The market is projected to witness significant gain during the forecast period owing to increasing collaboration within pharmaceutical companies. Also, factors such as increasing awareness among people regarding visceral pain are further anticipated to propel the market growth.

Browse Details of Report @https://www.hexaresearch.com/research-report/visceral-pain-market  

Hexa Research has segmented the global visceral pain market on the basis of therapeutics, indications and region:

Segmentation by therapeutics, 2014 - 2024 (USD Million)

• Analgesics

    • Narcotics

    • NSAID

• Pain modifiers

    • Tricyclic Antidepressants

    • Tricyclic Anticonvulsant

• Others

Segmentation by indications, 2014 - 2024 (USD Million)

• Interstitial cystitis

• Crohn’s

• Irritable bowel

• Chronic prostatitis

Segmentation by region, 2014 - 2024 (USD Million)

• North America

• Europe

• Asia Pacific

• Rest of the World (RoW)

Key players analyzed:

• Pfizer Inc.

• Allergan

• Johnson & Johnson

• Bayer AG

• Takeda Pharmaceutical Company Limited

• Mallinkrodt Pharmaceuticals

• AbbVie Inc.

• AstraZeneca

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/clinical-diagnostics-industry